A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00477425
|Study Director:||Jane Huang, M.D.||Genentech, Inc.|